First trimester exposure to topiramate and the risk of oral clefts in the offspring: A systematic review and meta-analysis

  • Alsaad A
  • Chaudhry S
  • Koren G
  • 28


    Mendeley users who have this article in their library.
  • 17


    Citations of this article.


Topiramate (TPM) is an increasingly used drug during childbearing ages for treatment of epilepsy, migraine, and appetite suppression as well as for off-label indications such as sleep and psychiatric disorders. Presently, while some reports suggested an increased risk of oral cleft (OC), these reports are balanced by studies that could not confirm such association. We conducted a meta-analysis of all studies reporting on women exposed to TPM during pregnancy. Of the 2327 publications reviewed, 6 articles met the inclusion criteria including 3420 patients and 1,204,981 controls. The odd ratio (OR) of OC after the first trimester exposure to TPM exposure was 6.26 (95% confidence interval: 3.13-12.51; P= 0.00001). This study provides strong evidence that TPM is associated with an increased risk of OC in infants exposed to TPM during embryogenesis and should lead to a careful review of TPM use in women of reproductive ages.

Author-supplied keywords

  • Epilepsy
  • Infants
  • Oral cleft
  • Pregnancy
  • Teratogenicity
  • Topamax
  • Topiramate

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Abdulaziz M.S. Alsaad

  • Shahnaz Akthar Chaudhry

  • Gideon Koren

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free